|
Zebrafish Models of Cancer
|
ZIABC010549
|
$572,098
|
$114,420
|
Hickstein, Dennis
|
CCR (NCI)
|
|
Zebrafish Chemical and Classical Genetics Approach to the Pathogenesis of T-ALL
|
7K08CA133103-05
|
$140,940
|
$140,940
|
Gutierrez, Alejandro
|
CHILDREN'S HOSPITAL BOSTON
|
|
Xenograft Model to Study Impact of CRLF2-Ligand in Hispanic Childhood B-ALL
|
1R21CA162259-01A1
|
$193,793
|
$193,793
|
PAYNE, KIMBERLY
|
LOMA LINDA UNIVERSITY
|
|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-15
|
$349,322
|
$41,919
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Vitamin D Analogs as Adjuvants in Chemotherapy of Cancer
|
2R01CA044722-22A1
|
$202,321
|
$101,161
|
Studzinski, George
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-22S1
|
$139,963
|
$2,799
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
5U10CA052784-22
|
$399,112
|
$7,982
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Validating Syk as a Target for AML Therapy
|
5R01CA140292-04
|
$352,231
|
$352,231
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INSTITUTE
|
|
Using game mechanics to improve outcomes among stem cell transplant survivors
|
1R41CA168107-01
|
$300,000
|
$150,000
|
McLaughlin, Jeffery
|
RADIANT CREATIVE GROUP, LLC
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-37S1
|
$50,000
|
$3,000
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-37S2
|
$246,000
|
$14,760
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-37S3
|
$74,999
|
$4,500
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-37
|
$6,285,726
|
$377,144
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
5P50CA100632-10
|
$2,300,000
|
$161,000
|
Kantarjian, Hagop
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-08S1
|
$140,000
|
$26,600
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-08S2
|
$75,000
|
$14,250
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support
|
5P30CA118100-08
|
$1,934,104
|
$367,480
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
Tyrosine kinase inhibitors for the treatment of childhood AML
|
5R01CA138744-03
|
$338,142
|
$338,142
|
BAKER, SHARYN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Tumor Microenvironment in Cancer Progression
|
ZIABC011332
|
$343,873
|
$34,387
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Transponson-based screens for genes involved in acute lymphoblastic Leukemia
|
5R01CA154998-02
|
$307,181
|
$153,591
|
Farrar, Michael
|
UNIVERSITY OF MINNESOTA
|
|
Toxicity Monitoring on Phase III Trials with Administrative Data
|
1R01CA165277-01A1
|
$495,102
|
$495,102
|
Aplenc, Richard
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Towards defining the functional methylome in acute lymphoblastic leukemia
|
5R00CA132784-04
|
$235,589
|
$235,589
|
TAYLOR, KRISTEN
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
|
The UT MD Anderson Cancer Center Community Clinical Oncology Program Research Bas
|
2U10CA045809-24
|
$1,389,595
|
$13,896
|
FISCH, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The role of PHF6 in T-cell acute lymphoblastic leukemia
|
5R01CA155743-02
|
$332,000
|
$332,000
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
|
5K08CA134649-05
|
$127,170
|
$127,170
|
Li, Qing
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
The role of HO-1 in Flt3-ITD positive AML proliferation and drug resistance
|
1F32CA171905-01
|
$49,859
|
$24,930
|
Irwin, Mary
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The role of fusion protein, OTT-MKL1, in acute megakaryoblastic leukemia
|
1F32CA165683-01
|
$33,715
|
$33,715
|
Kim, Yeun Hee
|
YALE UNIVERSITY
|
|
The role of AKT signaling in NOTCH1 induced leukemias
|
5R01CA129382-05
|
$324,613
|
$162,307
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-18S3
|
$4,829,857
|
$96,597
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-18S4
|
$75,000
|
$1,500
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-18S5
|
$76,389
|
$1,528
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Requirement for Trib2 in the Maintenance of Acute Myeloid Leukemia
|
1F31CA165813-01
|
$42,232
|
$42,232
|
Bailis, Will
|
UNIVERSITY OF PENNSYLVANIA
|
|
The Pathogenesis and Treatment of chronic GVHD
|
ZIABC011370
|
$40,978
|
$40,978
|
Williams, Kirsten
|
CCR (NCI)
|
|
The Glucocorticoid Receptor as Signal Integrator: Studying All Drug Resistance
|
5R00CA149088-04
|
$239,658
|
$239,658
|
PUFALL, MILES
|
UNIVERSITY OF IOWA
|
|
Temporal and Spatial Control of V(D)J Recombination
|
1R01CA160256-01A1
|
$336,150
|
$336,150
|
DESIDERIO, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Temporal and Spatial Control of V(D)J Recombination
|
3R01CA160256-01A1S1
|
$37,417
|
$37,417
|
DESIDERIO, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
TAS::75 0849::TAS INCREMENTAL FUNDING
|
261200800001E-51
|
$238,204,440
|
$40,672
|
HEIMBROOK, DAVID
|
SAIC-FREDERICK, INC.
|
|
Targeting to Epigenetic Modications in ALL
|
1R01CA176745-01
|
$402,250
|
$402,250
|
ARMSTRONG, SCOTT
|
DANA-FARBER CANCER INSTITUTE
|
|
Targeting SYK Tyrosine Kinase to Overcome Radiation Resistance in ALL
|
5R01CA154471-02
|
$332,000
|
$332,000
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Targeting SYK Kinase in B-Lineage ALL with CD19-Specific C-61 Nanoparticles
|
5U01CA151837-03
|
$456,297
|
$456,297
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Targeting non-classical oncogenes as therapy for T-ALL
|
1R01CA169162-01
|
$332,000
|
$166,000
|
Diacovo, Thomas
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Targeting Leukemia Stem Cells with Dietary Selenium
|
1R01CA162665-01A1
|
$303,222
|
$303,222
|
PRABHU, KUMBLE SANDEEP
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
Targeting an ATM-dependent metabolic pathway and FLT3 for AML therapy
|
1K22CA172757-01
|
$135,968
|
$135,968
|
GREGORY, MARK
|
UNIVERSITY OF COLORADO DENVER
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
5R01CA136551-04
|
$542,633
|
$271,317
|
Riddell, Stanley
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted therapy for 11q23 acute leukemias
|
5R01CA098459-07
|
$196,905
|
$196,905
|
HEMENWAY, CHARLES
|
LOYOLA UNIVERSITY CHICAGO
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-02
|
$317,475
|
$317,475
|
PANG, QISHEN
|
CHILDREN'S HOSPITAL MEDICAL CENTER CINCI
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
3U24CA114766-07S1
|
$499,863
|
$99,973
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
3U24CA114766-07S2
|
$1,488,625
|
$297,725
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
7U24CA114766-07
|
$1,329,162
|
$265,832
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-27S6
|
$3,781,672
|
$37,817
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
Total relevant funding to Childhood Leukemia for this search: $58,518,582
|